Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Free Report) has been given an average recommendation of “Buy” by the seven analysts that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $24.43.
A number of brokerages have recently issued reports on AVDL. Oppenheimer lifted their price target on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. HC Wainwright lowered their target price on shares of Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Avadel Pharmaceuticals in a report on Tuesday.
Read Our Latest Research Report on AVDL
Institutional Inflows and Outflows
Avadel Pharmaceuticals Stock Performance
NASDAQ:AVDL opened at $12.02 on Thursday. The stock has a market capitalization of $1.16 billion, a PE ratio of -15.21 and a beta of 1.47. Avadel Pharmaceuticals has a fifty-two week low of $10.39 and a fifty-two week high of $19.09. The company has a fifty day moving average of $13.62 and a two-hundred day moving average of $15.09.
Avadel Pharmaceuticals (NASDAQ:AVDL – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 92.12%. The firm had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. During the same period last year, the company posted ($0.41) EPS. Avadel Pharmaceuticals’s quarterly revenue was up 624.6% compared to the same quarter last year. Research analysts forecast that Avadel Pharmaceuticals will post -0.5 earnings per share for the current year.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Featured Stories
- Five stocks we like better than Avadel Pharmaceuticals
- The 3 Best Blue-Chip Stocks to Buy Now
- Rocket Lab is the Right Stock for the Right Time
- High Dividend REITs: Are They an Ideal Way to Diversify?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Stock Splits, Do They Really Impact Investors?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.